ASCO Publications
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Survival in Patients With Brain Metastases: Summary Report on the ...
2020年9月15日 · Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups.Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 …
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to …
2023年3月14日 · Recent data from US centers show that low-dose tamoxifen is the most popular choice of preventive therapy in women with high-risk lesions, with low discontinuation rates at 1 year compared with the standard dose and other preventive drugs. 5,6 To confirm the durability of the effect and assess long-term safety associated with 3 years of low-dose tamoxifen, here, …
Systemic Treatment of Patients With Metastatic Breast Cancer: …
2024年1月10日 · Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone.
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
2022年10月17日 · Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. 1 Almost 150,000 new cases and more than 50,000 deaths from CRC are reported each year in the United States. 2 In recent decades, the overall incidence of CRC has decreased among older adults because of screening and lifestyle factors; however, at the same time, …
Prevention and Management of Chemotherapy-Induced …
2020年7月14日 · The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged.Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop …
Antiemetics: ASCO Guideline Update | Journal of Clinical Oncology
2020年7月13日 · The systematic reviews included 3 publications from the updated search and 10 publications on CPIs. Two phase III trials in adult patients with non–small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the …
Vaccination of Adults With Cancer: ASCO Guideline
2024年3月18日 · ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow ...
When a Monoclonal Gammopathy Is Not Multiple Myeloma
2022年4月8日 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority …
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
In the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing approximately 200,000 new patients with brain metastases every year. 1 The point prevalence of brain metastases on initial diagnosis varies widely between different cancer histologies. For example, the incidence proportion of patients with metastatic …